Screener
BridgeBio Pharma BBIO Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Proceeds from common stock issuances under ESPP | 5,466 | 3,237 |
| Proceeds from stock option exercises, net of repurchases | 22,589 | 2,521 |
| Transactions with noncontrolling interests | — | 800 |
| Repurchase of RSU shares to satisfy tax withholding | (4,074) | (1,776) |
| Net cash provided by financing activities | 549,892 | 60,328 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 309,878 | (140,502) |
| Cash, cash equivalents, and restricted cash at beginning of period | 572,140 | 683,244 |
| Cash, cash equivalents, and restricted cash at end of period | $882,018 | $542,742 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's financing cash flow?
- BridgeBio Pharma (BBIO) reported financing cash flow of $549.89M in Q1 2026.
- How has BridgeBio Pharma's financing cash flow changed year-over-year?
- BridgeBio Pharma's financing cash flow increased by 811.5% year-over-year, from $60.33M to $549.89M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about BridgeBio Pharma's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude